MedTrace Logo

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

NCT01118754 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2011-11-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate if DE-101 ophthalmic suspension will safely and effectively improve signs and or symptoms of dry eye disease.

Conditions

  • Dry Eye

Interventions

DRUG

DE-101 ophthalmic suspension

Ophthalmic suspention; QID

DRUG

DE-101 ophthalmic suspension

Ophthalmic suspension; QID

DRUG

DE-101 ophthalmic suspension vehicle

ophthalmic suspension vehicle; QID

Sponsors & Collaborators

  • Santen Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01118754 on ClinicalTrials.gov